Repligen Corporation
corporate_fare Company Profile
Repligen Corporation (NASDAQ:RGEN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for RGEN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-30, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for RGEN spans 8-K, 424B3, S-4/A, S-4.
Recent high-impact activity:
- Repligen Refinances 2028 Notes With $1B Convertible Issue at 0.25%
- Repligen Posts Record $209M Q3 Revenue, Swings to $38.4M Loss on Impairment, Raises FY26 Guidance
- Repligen Posts 68-Cent Loss Per Share in Third Quarter
- Repligen Clears HSR Antitrust Review for $1.5B BioLife Acquisition
- Repligen Sets October 5 Vote on $1.5B BioLife Acquisition
Financial Snapshot
Short Interest & Short Volume
4.88 days to coverFINRA reported short interest of 7,145,036 shares in RGEN as of the October 15, 2026 settlement, a 5.8% decrease from the prior period — about 4.9 days to cover at its recent average daily volume. On October 29, 2026, 57.4% of RGEN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.